Skip to content

GORE INTERING Vascular Graft IRS47045LRecalls & reported problems

W. L. Gore & Associates, Inc. · INTERING VASC GRAFT STR SW IR 4-7mmX45cm 38cm Rings Tapered · Class 2 · Implant

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
2
Deaths reported
0
Injuries reported
2
Recalls naming it
0

Summary

The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 00733132607204), received between Jun 6, 2022 and Jun 6, 2022 — classified as 2 injuries.

The most frequently reported specific device problem is “Patient Device Interaction Problem” (2 reports).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Most reported problems

Device problems

  • Patient Device Interaction Problem2

Patient problems

  • Hematoma2

Recent adverse event reports

The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.

  • InjuryJun 6, 2022Patient Device Interaction Problem; Patient Device Interaction Problem

    THE FOLLOWING INFORMATION WAS REPORTED TO GORE: ON DECEMBER 2, 2021, A GORE® INTERING® VASCULAR GRAFT WAS INTENDED FOR HEMODIALYSIS TREATMENT. ON (B)(6) 2022, THE PATIENT PRESENTED WITH SEROMA. A GORE® INTERING® VASCULAR GRAFT WAS SEWN IN AS A INTERPOSITION GRAFT. ON APRIL 20, 2022, THE PATIENT PRESENTED WITH SEROMA. A GORE® VIABAHN® ENDOPROSTHESIS (VSX DEVICE) WAS ENDOVASCULARLY PLACED TO RELINE THE SECOND GORE® INTERING® VASCULAR GRAFT, FOR TREATMENT OF ULTRAFILTRATION. ULTRAFILTRATION WAS IDENTIFIED DURING THE PROCEDURE AFTER THE VSX DEVICE WAS SUCCESSFULLY IMPLANTED. ON (B)(6) 2022, THE GORE® INTERING® VASCULAR GRAFT, AND VSX DEVICE WERE EXPLANTED. 2203-A:-OTHER CODE (POST-OPERATIVE FLUID LEAKAGE THROUGH VSX DEVICE WALL AFTER ESTABLISHMENT OF BLOOD FLOW).

    Patient problems: Hematoma

    MAUDE report 14604839 ↗
  • InjuryJun 6, 2022Patient Device Interaction Problem; Patient Device Interaction Problem

    THE FOLLOWING INFORMATION WAS REPORTED TO GORE: ON (B)(6) 2021, A GORE® INTERING® VASCULAR GRAFT WAS INTENDED FOR HEMODIALYSIS TREATMENT. ON (B)(6) 2022, THE PATIENT PRESENTED WITH SEROMA. A GORE® INTERING® VASCULAR GRAFT WAS SEWN IN AS A INTERPOSITION GRAFT. ON (B)(6) 2022, THE PATIENT PRESENTED WITH SEROMA. A GORE® VIABAHN® ENDOPROSTHESIS (VSX DEVICE) WAS ENDOVASCULARLY PLACED TO RELINE THE SECOND GORE® INTERING® VASCULAR GRAFT, FOR TREATMENT OF ULTRAFILTRATION. ULTRAFILTRATION WAS IDENTIFIED DURING THE PROCEDURE AFTER THE VSX DEVICE WAS SUCCESSFULLY IMPLANTED. ON (B)(6) 2022, THE GORE® INTERING® VASCULAR GRAFT, AND VSX DEVICE WERE EXPLANTED. (B)(4).

    Patient problems: Hematoma

    MAUDE report 14603491 ↗

Other PROSTHESIS, VASCULAR GRAFT, OF 6MM AND GREATER DIAMETER devices

All PROSTHESIS, VASCULAR GRAFT, OF 6MM AND GREATER DIAMETER devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page